← Cytek Biosciences, Inc. CTKB
Market Price
$4.69
Market Cap
$631.51M
P/E Ratio
N/A
Revenue (FY 2025)
↑0.5% YoY
$201.49M
3-Yr CAGR: 7.1%
Net Income
↓-1,005.3% YoY
-$66.54M
Net Margin: -33.0%
Free Cash Flow
↓-140.1% YoY
-$8.77M
FCF Yield: -1.39%
EPS (Diluted)
↓-940.0% YoY
$-0.52
Basic: $-0.52
Return on Equity
Efficiency
-19.5%
ROA: -340.7%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (CTKB)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2020 | $92.8M | — | $51.7M | $19.4M | — | $0.10 | — | $15.2M | $13.6M | — |
| FY 2021 | $128.0M | +37.8% | $79.1M | $3.0M | -84.4% | — | -100.0% | $4.6M | $0.3M | -98.0% |
| FY 2022 | $164.0M | +28.2% | $101.0M | $2.5M | -17.9% | $0.02 | — | $-12.2M | $-22.0M | -8,362.8% |
| FY 2023 | $193.0M | +17.7% | $109.4M | $-12.1M | -589.0% | $-0.09 | -550.0% | $5.3M | $0.6M | +102.9% |
| FY 2024 | $200.5M | +3.9% | $111.1M | $-6.0M | +50.4% | $-0.05 | +44.4% | $25.4M | $21.9M | +3,352.4% |
| FY 2025 | $201.5M | +0.5% | $104.5M | $-66.5M | -1,005.3% | $-0.52 | -940.0% | $-4.7M | $-8.8M | -140.1% |
Valuation
Market Price
$4.69
Market Cap
$631.51M
Enterprise Value
N/A
P/E Ratio
N/A
P/B Ratio
1.77
FCF Yield
-1.39%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
51.84%
Operating Margin
-20.04%
Net Margin
-33.02%
Return on Equity (ROE)
-19.47%
Return on Assets (ROA)
-340.70%
Asset Turnover
10.32x
Revenue 3-Yr CAGR
7.10%
Financial Health & Liquidity
Current Ratio
0.83
Cash Ratio
3.88
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$90.85M
Total Debt
N/A
Book Value / Share
$2.65
Cash Flow Efficiency
Operating Cash Flow
-$4.69M
Capital Expenditures (CapEx)
$4.08M
Free Cash Flow
-$8.77M
OCF / Revenue
-2.33%
FCF / Revenue
-4.35%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$-0.52
EPS (Basic)
$-0.52
Dividends / Share
N/A
Book Value / Share
$2.65
EPS YoY Growth
-940.00%
Balance Sheet (FY 2025)
Total Assets
$19.53M
Total Liabilities
$23.42M
Stockholders' Equity
$341.74M
Current Assets
$19.53M
Current Liabilities
$23.42M